A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation | MicrobiomeTrials
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-04-07Est. Completion: 2029-07-27
Enrollment target: 130 participants
Locations
Mayo Clinic - Cancer Center - Phoenix, Phoenix, Arizona, United States
City of Hope - Duarte Cancer Center, Duarte, California, United States
UC San Diego Health - Moores Cancer Center, San Diego, California, United States
Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's, Denver, Colorado, United States
Icahn School of Medicine at Mount Sinai - Oncology, New York, New York, United States
NEXT Dallas - Oncology Department, Irving, Texas, United States
START | San Antonio, San Antonio, Texas, United States
Border Medical oncology - Albury Wodonga Regional Cancer Centre, Albury, New South Wales, Australia
Calvary Mater Hospital Newcastle - Oncology, Waratah, New South Wales, Australia
Cabrini Health Oncology Research, Malvern, Victoria, Australia
Ghent University Hospital | Drug Research Unit Department, Ghent, Belgium
Rigshospitalet - Kræftbehandling, Copenhagen, Capital Region, Denmark
Odense University Hospital - Oncology Department, Odense, Region Syddanmark, Denmark
HUS-Yhtymä, Helsingin yliopistollinen sairaala (HUS) - Syöpäkeskus, Helsinki, Uusimaa, Finland
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I, Roma, Italy
Nederlands Kanker Instituut, Amsterdam, North Holland, Netherlands
National University Hospital Medical Centre, Singapore, Singapore
National Cancer Center Singapore - Oncology Department, Singapore, Singapore
Hospital Universitari Vall D Hebron | Oncologia, Barcelona, Spain